Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H17N5O7S3 |
Molecular Weight | 523.563 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C4=CSC(N)=N4)C(O)=O
InChI
InChIKey=ZBHXIWJRIFEVQY-IHMPYVIRSA-N
InChI=1S/C19H17N5O7S3/c1-30-23-11(9-7-34-19(20)21-9)14(25)22-12-15(26)24-13(17(27)28)8(5-32-16(12)24)6-33-18(29)10-3-2-4-31-10/h2-4,7,12,16H,5-6H2,1H3,(H2,20,21)(H,22,25)(H,27,28)/b23-11-/t12-,16-/m1/s1
Molecular Formula | C19H17N5O7S3 |
Molecular Weight | 523.563 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugs.com/vet/naxcel.htmlCurator's Comment: Description was created based on several sources, including https://www.zoetisus.com/dairy/avoidresidues/PDF/EXCEDE_PRESCRIBING_INFO.pdf and http://www.ncbi.nlm.nih.gov/pubmed/12052187
Sources: https://www.drugs.com/vet/naxcel.html
Curator's Comment: Description was created based on several sources, including https://www.zoetisus.com/dairy/avoidresidues/PDF/EXCEDE_PRESCRIBING_INFO.pdf and http://www.ncbi.nlm.nih.gov/pubmed/12052187
Ceftiofur is an antibiotic of the cephalosporin type (third generation), licensed for use in veterinary medicine only. It was first described in 1987. It is marketed by pharmaceutical company Zoetis as Excenel, Naxcel, and Excede and is also the active ingredient in that company's Spectramast LC (lactating cow formulation) and Spectramast DC (dry cow formulation) product. Ceftiofur has worldwide approvals for respiratory disease in swine, ruminants (cattle, sheep and goats) and horses and has also been approved for foot rot and metritis infections in cattle. Ceftiofur has also been approved in various countries for early mortality infections in day-old chicks and turkey poults. Ceftiofur (NAXCEL) is indicated for treatment of bovine respiratory disease (shipping fever, pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. NAXCEL is also indicated for treatment of acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3631686
Curator's Comment: First described in 1987
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Staphylococcus aureus growth |
|||
Target ID: Mannheimia haemolytica growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/22914822 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | NAXCEL Sterile Powder Approved UseIndicated for treatment of bovine respiratory disease (shipping fever, pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. NAXCEL Sterile Powder is also indicated for treatment of acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus Launch Date2006 |
|||
Curative | SPECTRAMAST DC Sterile Suspension Approved UseSPECTRAMAST DC Ceftiofur Hydrochloride Sterile Suspension is indicated for the treatment of subclinical mastitis in dairy cattle at the time of dry off associated with Staphylococcus aureus, Streptococcus dysgalactiae, and Streptococcus uberis. Launch Date2005 |
PubMed
Title | Date | PubMed |
---|---|---|
PHARMACOKINETICS OF CEFTIOFUR CRYSTALLINE FREE ACID, A LONG-ACTING CEPHALOSPORIN, IN AMERICAN FLAMINGOS (PHOENICOPTERUS RUBER). | 2016 Jun |
|
Randomized noninferiority trial comparing 2 commercial intramammary antibiotics for the treatment of nonsevere clinical mastitis in dairy cows. | 2016 Oct |
|
Randomized, controlled clinical trial on the efficacy of nonsteroidal antiinflammatory drugs for the treatment of acute puerperal metritis in dairy cows. | 2016 Oct |
|
Plasma, subcutaneous tissue and bone concentrations of ceftiofur sodium after regional limb perfusion in horses. | 2017 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/vet/naxcel.html
Curator's Comment: Can also be administered subcutaneously
Administer to cattle by intramuscular or subcutaneous injection at the dosage of 0.5 to 1.0 mg ceftiofur per pound (1.1 to 2.2 mg/kg) of body weight (1-2 mL reconstituted sterile solution per 100 lbs body weight). Treatment should be repeated at 24-hour intervals for a total of three consecutive days. Additional treatments may be given on days four and five for animals which do not show a satisfactory response (not recovered) after the initial three treatments. Selection of dosage (0.5 to 1.0 mg/lb) should be based on the practitioner’s judgement of severity of disease.
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/20948169
Ceftiofur had the highest in vitro activity with an MIC(50) of 2.2 ug/ml against isolates of A. pleuropneumoniae collected from pigs with hemorrhagic pneumonia
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:19:43 GMT 2023
by
admin
on
Sat Dec 16 16:19:43 GMT 2023
|
Record UNII |
83JL932I1C
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QJ01DD90
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
||
|
CFR |
21 CFR 522.313
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
NAXCEL [AUTHORIZED]
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
||
|
CFR |
21 CFR 556.113
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
||
|
CFR |
21 CFR 526.313
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
NAXCEL [AUTHORIZED]
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
||
|
CFR |
21 CFR 522.313A
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
||
|
WHO-VATC |
QJ01DD99
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
||
|
WHO-VATC |
QJ51DD90
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000081834
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
PRIMARY | |||
|
CHEMBL222913
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
PRIMARY | |||
|
7445
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
PRIMARY | |||
|
83JL932I1C
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
PRIMARY | |||
|
6328657
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
PRIMARY | |||
|
DB11485
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
PRIMARY | |||
|
C81036
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
PRIMARY | |||
|
DTXSID7046702
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
PRIMARY | |||
|
80370-57-6
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
PRIMARY | |||
|
5703
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
PRIMARY | |||
|
m3221
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
PRIMARY | Merck Index | ||
|
CEFTIOFUR
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
PRIMARY | |||
|
SUB07426MIG
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
PRIMARY | |||
|
1311521
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
PRIMARY | RxNorm | ||
|
83JL932I1C
Created by
admin on Sat Dec 16 16:19:43 GMT 2023 , Edited by admin on Sat Dec 16 16:19:43 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |